2nd Annual NASDAQ TASE Israeli Investor Conference Dan Suesskind, CFO Teva Pharmaceutical Industries Ltd. November 27, 2007.

Presentation on theme: "2nd Annual NASDAQ TASE Israeli Investor Conference Dan Suesskind, CFO Teva Pharmaceutical Industries Ltd. November 27, 2007."— Presentation transcript:

1 2nd Annual NASDAQ TASE Israeli Investor Conference Dan Suesskind, CFO Teva Pharmaceutical Industries Ltd. November 27, 2007

2 2 TODAY’S PRESENTATION CONTAINS FORWARD LOOKING STATEMENTS WHICH EXPRESS THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT. SUCH STATEMENTS ARE BASED ON CURRENT EXPECTATIONS AND INVOLVE A NUMBER OF KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES THAT COULD CAUSE TEVA’S FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS TO DIFFER SIGNIFICANTLY FROM THE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARD-LOOKING STATEMENTS. IMPORTANT FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE TEVA’S ABILITY TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE ADDITIONAL PHARMACEUTICAL PRODUCTS, THE INTRODUCTION OF COMPETITIVE GENERIC PRODUCTS, THE IMPACT OF COMPETITION FROM BRAND-NAME COMPANIES THAT SELL THEIR OWN GENERIC PRODUCTS OR SUCCESSFULLY EXTEND THE EXLUSIVITY PERIOD OF THEIR BRANDED PRODUCT, TEVA’S ABILITY TO RAPIDLY INTEGRATE THE OPERATIONS OF ACQUIRED BUSINESSES, THE AVAILABILITY OF PRODUCT LIABILITY COVEREGE IN THE CURRENT INSURANCE MARKET, THE IMPACT OF PHARMACEUTICAL INDUSTRY REGULATION AND PENDING LEGISLATION THAT COULD AFFECT THE PHARMACEUTICAL INDUSTRY, THE DIFFICULTY OF PREDICTING U.S. FOOD AND DRUGS ADMINISTRATION (“FDA”) AND OTHER REGULATORY AUTHORITY APPROVALS, THE REGULATORY ENVIRONMENT AND CHANGES IN THE HEALTH POLICIES AND STRUCTURE OF VARIOUS COUNTRIES, ACCEPTANCE AND DEMAND FOR NEW PHARMACEUTICAL PRODUCTS AND NEW THERAPIES, UNCERTAINTIES REGARDING MARKET ACCEPTANCE OF INNOVATIVE PRODUCTS NEWLY LAUNCHED, CURRENTLY BEING SOLD OR IN DEVELOPMENT, THE IMPACT OF RESTRUCTURING OF CLIENTS, RELIANCE ON STRATEGIC ALLIANCES, EXPOSURE TO PRODUCT LIABILITY CLAIMS, DEPENDENCE ON PATENT AND OTHER PROTECTIONS FOR INNOVATIVE PRODUCTS, FLUCTUATIONS IN CURRENCY, EXCHANGE AND INTEREST RATES, OPERATING RESULTS, OTHER FACTORS THAT ARE DISCUSSED IN TEVA’S ANNUAL REPORT ON FORM 20-F AND ITS OTHER FILINGS WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (“SEC”). FORWARD LOOKING STATEMENTS SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE, AND THE COMPANY UNDERTAKES NO OBLIGATION TO UPDATE PUBLICLY OR REVISE ANY FORWARD LOOKING STATEMENTS, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE. Makep 4,5,9 Forward-Looking Statements

3 3 Overview Vertically-integrated global pharmaceutical company founded in 1901 Three main business segments – Finished Dosage Generic Pharmaceuticals – Active Pharmaceutical Ingredients (API) – Specialty Branded Pharmaceuticals Presence in 60 countries; approximately 26,000 employees Rank among the top 20 in revenues among all pharmaceutical companies

4 4 1-9/071-9/06% Change Sales ($ Millions) 6,832 6,13111% Net Income ($ Millions) 1,382 1,434(4%) Earnings per Share (diluted $) 1.69 1.77(5%) Cash Flow from Operations 1,268 1,294 P/E Ratio 2007 (F.C. Consensus $2.32) 19 Market Capitalization (as of Nov. 20, 2007: $44.75) $35 B Financial Strength

5 5 1-9/07: $6,832 Million * Western Europe and Hungary ** TSP as % of North America Makep 5,4,3,7,8,9 North America, 58%North America, 61% 1-9/06: $6,131 Million Sales By Region Total Int. 16%

6 6 Teva’s Core Strengths in Generics Managing the Environment R&D Portfolio Global Reach Operations in over 50 countries Technology Development Oral and Semi solids Injectables Modified Release Inhalation Intellectual Property Approximately 1000 Issued Patents API/ Vertical Integration Approximately 250 Compounds Global Supply Chain Over 40 Production facilities

7 7 Q3/2007 – North America Pharmaceutical Sales ($ Millions) CAGR = 31% Makep 30

8 8 Absolute growth of generics takes off in the last four years; brands decline

9 9 Generic TRx continue to gain traction 12%

10 10 Generic Industry Consolidation IMS TRx MAT Jun-97 (Top 4 = 35%) IMS TRx MAT Jun-07 (Top 4 = 55%) Top 4 have 55% market share combined

11 11 Total Rx ’ s Generic companies onlyAll pharmaceutical companies Top U.S. Pharmaceutical Companies (In thousands) *Increase over MAT 09/2006 Source: IMS Health September 2007 NPA 1Teva USA443,824 2Mylan 278,627 3Pfizer 269,682 4 Novartis 267,918 5Watson223,674 6Barr 137,671 7Merck 120,555 8AstraZeneca111,617 9GlaxoSmithKline109,903 10 Mallinckrodt97,291 1Teva USA431,054 2Mylan 276,753 3Watson 223,671 4 Sandoz 192,609 5Barr137,581 6Mallinckrodt 97,291 7Actavis 84,689 8Qualitest81,167 9Greenstone77,598 10 Par71,370

12 12 Competitive Generic TRX share* Simvastatin # of ANDA’s: 12 Teva51.9% Dr. Reddy – AG23.9% Aurobindo7.1% Ranbaxy6.5% Lupin4.1% Sandoz2.6% Zydus2.2% Other1.7% Sertraline # of ANDA’s: 16 Greenstone – AG53.9% Teva33.7% Apotex4.7% Lupin3.7% Sandoz1.4% Aurobindo0.6% Westward0.4% Other1.6% Pravastatin 10/20/40 # of ANDA’s: 10 Teva46.9% Apotex28.1% Watson – AG9.4% Dr Reddy9.4% Sandoz4.2% Par0.7% Other1.3% Zolpidem # of ANDA’s: 14 Teva41.9% Prasco – AG14.3% Mylan¹11.8% Dr Reddy7.4% Sandoz6.5% Caraco5.7% Apotex5.0% Other7.4% * Week of October 12, 2007 ¹ Includes Genpharm

13 13 U.S. Generic Industry ’ s Largest Pipeline 151 ANDAs – over $88 billion in total brand sales 82 Paragraph IV Filings 43 First-to-File – over $38 billion in total brand sales Makep 4,3,5 As of October 26, 2007

14 14 Q3/2007 – Europe* Pharmaceutical Sales ($ Millions) CAGR = 33% Up 22 % * Western Europe and Hungary Makep 31

15 15 Western Europe is emerging as a pharmacy-focused region, facilitating higher penetration Pharmacist / Payer influence Physician influence Source:Teva Europe Hungary Italy France UK Netherlands Branded Gx model Substitution Gx model Germany Spain Market discontinuities Generic penetration

16 16 Q3/2007 – International (ROW) Pharmaceutical Sales ($ Millions) CAGR = 42% Up 12% Makep 37

17 17 Teva’s API division is the Industry leader for active pharmaceutical ingredients (API) for generics Manufactures and sells approx. 250 products to Teva's finished pharmaceutical product businesses and to third parties Be First – Stay Last Provides Teva with strategic advantages through vertical integration A major source for Teva’s R&D and finished products Provides Teva a strong competitive advantage – capital expenditures, strong IP and leading worldwide expertise make Teva’s API capabilities hard to replicate 18 production sites located in Israel, U.S., Mexico, Switzerland, Hungary, Italy and India + TAPI – Teva Active Pharmaceutical Ingredients

18 18 Makep 1,2,3,4,5,6,7,10,9, 32 Internal Third Party 654 940 1,046 1,067 Down 3% Down 6% Up 36% Down 5% 996 1,327 Up 12% Up 24% Teva API Sales ($ Millions)

19 19 Q3/2007 – Copaxone® In-Market Global Sales ($ Millions) 1,176 720 Up 20% 17% Up 24% 936 1,414 26% US Non US Makep 5,4,9,20,1,2,3 Q3/06Q3/07 25% 24% 354 441

20 20 Next Milestone Submission To FDA – H2 /2008 Copaxone® 40 mg Copaxone®, at a 40 mg/day dose, has the potential to provide better efficacy compared to all approved first-line treatments Results of 9-month Phase II study, which compared to Copaxone® 20 mg/day – Patients taking the higher dose showed a 38% greater reduction in inflammatory disease activity as measured by MRI – Reduced mean on-trial relapse rate of 77% vs. 62% Phase III study (“FORTE”) initiated in July 2006

21 21 Laquinimod A novel, oral product for relapsing MS Licensed from Sweden’s Active Biotech Positive results of Phase IIb study – Demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced MRI disease activity by 55 percent in RRMS patients – Favorable trend towards reducing annual relapse rates, the number of relapse-free patients and time to first relapse compared with placebo – Confirmed favorable safety profile Next Milestone Phase III studies

22 22 Azilect ® for Parkinson’s disease Novel, potent, second generation, selective MAO-B Inhibitor approved for both monotherapy in early disease and adjunct therapy in more advanced stages Now available in 29 countries since initial launch in Israel in early 2005 Offers patients the benefit of unique combination of efficacy with convenient once daily dosing, no titration and good tolerability ADAGIO study in close to 1200 patients – aims to demonstrate Azilect ® as disease modifying therapy (results expected H2 2008)

23 23 IMS NPA 10/26/07 SABA TRx Weekly Market (Share)

24 24 IMS NPA 10/26/07 SABA-HFA TRx Market (Share)

25 25 Marketed products End of Phase III 2009-2010 End of Phase III 2011 and beyond Multiple Sclerosis Copaxone ® Parkinson’s Azilect ® Respiratory QVAR ® Albuterol ® HFA Hemato-Oncology (Phase II) Solid Tumor Oncology (Phase II) ALS (Phase II) Innovative Products and Growth Opportunities Hemato-oncological (Phase II/III) Parkinson’s Disease modification * Potential sales include respiratory products MS (Oral Phase III) Multiple Sclerosis Increased efficacy Lupus (Phase II) CIS Copaxone ® Alzheimer (Phase II)

26 26 We Focus on Shareholder Value Makep 2,3,4,5,8,9

27 27 Cash Flow Highlights ($ Millions)Q3/07Q2/07Q1/07Q4/06Q3/06Q2/06YR2006 Net Income 525 515 342 461 606 488 546 Cash flow from operating activities 332 437 499 765 793 212 2,058 Acquisition of companies 17 - - 5 2 24 3,587 Purchase of fixed assets (net of proceeds from sale) 104 106 149 129 76 90 366 Dividends * 73 75 72 58 59 57 229 Free cash flow ** 155 256 278 578 658 65 1,463 * Actually distributed ** Net cash provided by operating activities less purchase of property, plant and equipment (net), and dividends paid

28 28 Financial Strength ($ Billions)30-Sep-200730-Jun-2007 Total Equity 12.92 B 12.06 B Total Debt 5.31 B 5.51 B of which: short-term 1.95 B 1.52 B long-term * 3.36 B 3.98 B Leverage **29%31% * Includes both converts of $1.4 bn and straight debt of $1.5 mn issued on Q1/06 ** [DEBT/(Debt+Equity)]

29 29 Consolidated Statement of Income ($ Millions) % of Sales ($ Millions)Q3/07Q2/07Q1/07Q4/06Q3/06Q3/07Q2/07Q1/07Q4/06Q3/06 Sales 2,366 2,386 2,080 2,277 2,286100% Gross profit 1,250 1,243 1,037 1,103 1,26253%52%50%48%55% R&D – net 141 137 135 137 1356% S&M expenses 304 301 304 321 25113% 15%14%11% G&A expenses 154 168 152 157 1537% Total SG&A expenses 458 469 456 478 40419%20%22%21%18% Operating income 651 637 446 488 72328%27%21% 32% Financial expenses - net 3 8 28 (4) 280% 1%0%1% Income before taxes 648 629 418 492 69527%26%20%22%30% Net income 525 515 342 433 60622% 16%19%27% Earnings per share (Diluted) 0.64 0.63 0.42 0.53 0.74 Tax Rate 19.2%18.0% (15.7%)12.5%19.2%18.0% (15.7%)12.5%

30 30 Makep 1,2,3,4,5,6,7,10,9, 32 Sales (in $ Millions) +11% CAGR = 37%

31 31 Makep 1,2,3,4,5,6,7,10,9, 32 R&D (in $ Millions) CAGR = 32% +15%

32 32 Makep 1,2,3,4,5,6,7,10,9, 32 Dividends (in $ Millions) +29% CAGR = 41%

33 33 NASDAQ Top 20 Companies As of Nov. 17, 2007 * * Share Price: $44.62

34 34 Increasing demand globally for generics Expanding global market reach The generic industry’s leading product offering Unmatched vertical integration The industry’s most robust generic pipeline Growing specialty pharmaceutical business / pipeline Promising Biogenerics opportunities Teva’s growth is fueled by: Driving Growth, Expanding Leadership

35 2nd Annual NASDAQ TASE Israeli Investor Conference Dan Suesskind, CFO Teva Pharmaceutical Industries Ltd. November 27, 2007